Chapter 11 – Nuclear Medicine

[1]  K. Hasuo,et al.  High [18F]FDG Uptake in Primary Cerebral Lymphoma: A PET Study , 1988, Journal of computer assisted tomography.

[2]  S. Reske,et al.  Vortäuschung eines mediastinalen Non-Hodgkin-Lymphomrezidivs durch diffuse Thymushyperplasie im 18F-FDG-PET , 1996 .

[3]  U. Jaeger,et al.  Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation , 2002, Leukemia.

[4]  E. Merkle,et al.  Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.

[5]  A. Lammertsma,et al.  18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[6]  G. Jerusalem,et al.  Does positron emission tomogrpahy have a role in routine clinical practice in patients with Hodgkin's disease? , 2002, Clinical lymphoma.

[7]  M. Phelps,et al.  Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. , 2003, Chest.

[8]  V. Diehl,et al.  Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.

[9]  G. Leverger,et al.  [18F]FDG in childhood lymphoma: clinical utility and impact on management , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  A. Buck,et al.  Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography , 1998, European Journal of Nuclear Medicine.

[11]  I. Kirkwood,et al.  Erythema Nodosum Associated With Diffuse, Large B-Cell Non-Hodgkin Lymphoma Detected by FDG PET , 2003, Clinical nuclear medicine.

[12]  A. Sundin,et al.  [18F] FDG PET in gastric non-Hodgkin's lymphoma. , 1997, Acta oncologica.

[13]  M. O’connell,et al.  Role of 67gallium citrate scanning in the management of non‐hodgkin's lymphoma , 1975, Cancer.

[14]  M. Sasaki,et al.  Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma , 2003, Annals of nuclear medicine.

[15]  N. Avril,et al.  Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Hustinx,et al.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Wildberger,et al.  Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.

[18]  K. Hwang,et al.  False-positive F-18 FDG gamma camera positron emission tomographic imaging resulting from inflammation of an anterior mediastinal mass in a patient with non-Hodgkin's lymphoma. , 2001, Clinical nuclear medicine.

[19]  F. Gherlinzoni,et al.  The role of positron emission tomography (PET) in the management of lymphoma patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  H. Shirato,et al.  Early Detection of Bone Marrow Involvement in Extramedullary Plasmacytoma by Whole-Body F-18 FDG Positron Emission Tomography , 2000, Clinical nuclear medicine.

[21]  D. Bumann,et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  D Front,et al.  Gallium 67 imaging in monitoring lymphoma response to treatment , 1988, Cancer.

[23]  D. J. King,et al.  Gallium scanning in lymphoma. , 1980, Clinical radiology.

[24]  J Kotzerke,et al.  Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  B. Beuthien-Baumann,et al.  Simultaneous occurrence of Hodgkin's lymphoma and eosinophilic granuloma: a potential pitfall in positron emission tomography imaging. , 2002, Clinical lymphoma.

[26]  U. Cremerius,et al.  Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. , 1998, Nuclear medicine communications.

[27]  A. Biggi,et al.  Revisiting the prognostic role of gallium scintigraphy in low-grade Non-Hodgkin’s lymphoma , 1997, European Journal of Nuclear Medicine.

[28]  S. Reske,et al.  18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Drossman,et al.  Lymphoma of the mediastinum and neck: evaluation with Ga-67 imaging and CT correlation. , 1990, Radiology.

[30]  P. Hoffer,et al.  The role of gallium-67 in the clinical evaluation of cancer. , 1984, Seminars in nuclear medicine.

[31]  S. Hain,et al.  18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  G. Jerusalem,et al.  Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. , 1999, Nuclear medicine communications.

[33]  H. Heimpel,et al.  Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment , 1999 .

[34]  D. Costa,et al.  Challenging cases and diagnostic dilemmas: case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Hoffman,et al.  Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET) , 1996, International journal of STD & AIDS.

[36]  S. P. Gill,et al.  Gallium citrate Ga 67 scanning: clinical usefulness in lymphoma patients. , 1976, Archives of internal medicine.

[37]  B Y Yeap,et al.  Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  O. Israel,et al.  Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Krug,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease , 2001, Annals of Hematology.

[40]  R. Fisher,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. , 2002, The American journal of medicine.

[41]  R. Mansberg,et al.  Tl-201 and Ga-67 scintigraphy in non-Hodgkin's lymphoma. , 1999, Clinical nuclear medicine.

[42]  J Kotzerke,et al.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. , 1997, Radiology.

[43]  A. Chott,et al.  Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Patrick Dupont,et al.  [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  U. Jäger,et al.  F-Fluorodeoxyglucose Positron Emission Tomography ( 18 F-FDG-PET ) for Staging and Follow-Up of Marginal Zone B-Cell Lymphoma , 2003 .

[46]  P. Mikosch,et al.  Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma. , 2003, Acta medica Austriaca.

[47]  E. Yoshikawa,et al.  Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  R. Schilsky,et al.  Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin's lymphoma. , 1980, The American journal of medicine.

[49]  Frank Grünwald,et al.  Positron Emission Tomography for the Staging of Hodgkin's Lymphoma - Increasing the Body of Evidence in Favor of the Method , 2002, Acta oncologica.

[50]  S. Ben-Haim,et al.  Diffuse lung uptake of Ga-67 after treatment of lymphoma: is it of clinical importance? , 1996, Radiology.

[51]  J Kotzerke,et al.  2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma , 2001, Cancer.

[52]  S. Reske,et al.  Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography , 2000, European Journal of Nuclear Medicine.

[53]  H. Schirrmeister,et al.  Positron emission tomography (PET) for staging of solitary plasmacytoma. , 2003, Cancer biotherapy & radiopharmaceuticals.

[54]  A. Padhani,et al.  Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? , 2000, European journal of cancer.

[55]  J. Leonard,et al.  Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma , 2002, Cancer.

[56]  R. Hustinx,et al.  18F-FDG PET in children with lymphomas , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  S. Hain,et al.  2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  Kazutaka Hayashi,et al.  Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma , 2002, Annals of nuclear medicine.

[59]  Z. Keidar,et al.  Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study. , 2003, Radiology.

[60]  P. Roach,et al.  Comparison of thallium-201 and gallium-67 scintigraphy in the evaluation of non-Hodgkin's lymphoma. , 1998, Australian and New Zealand journal of medicine.

[61]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  B Beuthien-Baumann,et al.  Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma , 2001, British journal of haematology.

[63]  F. Maul,et al.  Whole body positron emission tomography in the treatment of Hodgkin disease , 2001, Cancer.

[64]  S. Barrington,et al.  Fluoro‐deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma , 2002, British journal of haematology.

[65]  R. Hustinx,et al.  The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  M. Macro,et al.  Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy , 2000, European Journal of Nuclear Medicine.

[67]  Mahlon D. Johnson,et al.  Evaluating Contrast-Enhancing Brain Lesions in Patients with AIDS by Using Positron Emission Tomography , 1995, Annals of Internal Medicine.

[68]  S. Ben-Haim,et al.  Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  P. Kahn,et al.  Clinical usefulness of 67gallium scanning in the malignant lymphomas. , 1976, The American journal of medicine.

[71]  I. Magrath,et al.  High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  R. Hicks,et al.  Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. , 2003, Clinical lymphoma.

[73]  J. Radford,et al.  Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records , 1997, BMJ.

[74]  R. Buchert,et al.  18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[76]  R. Hustinx,et al.  Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[77]  M. Kaminski,et al.  Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.

[78]  O. Israel,et al.  The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. , 1995, Seminars in nuclear medicine.

[79]  S. Hain,et al.  18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.

[80]  R. Hustinx,et al.  PET scan imaging in oncology. , 2003, European journal of cancer.

[81]  P. Dupont,et al.  Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.

[82]  J. Kriss,et al.  Gallium‐67 citrate scanning in Hodgkin's disease and non‐Hodgkin's lymphoma , 1976, Cancer.

[83]  G Hör,et al.  Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. , 1999, Leukemia & lymphoma.

[84]  A. Alavi,et al.  Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging. , 2003, Clinical Nuclear Medicine.

[85]  L. Kostakoglu,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? , 2000, European Journal of Nuclear Medicine.

[86]  H. Döhner,et al.  Initial results in the assessment of multiple myeloma using 18F-FDG PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[87]  G. Jerusalem,et al.  Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. , 2002, Clinical lymphoma.

[88]  P. Dupont,et al.  Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. , 2003, Blood.

[89]  B. Van Den Bossche,et al.  18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients , 2002, Nuclear medicine communications.

[90]  A. Chott,et al.  18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma , 2003, Gut.